NBCD attending OARSI 2022April 07, 2022 As a part of our dedication to scientific advancements in the research field of OA, we will be attending the OARSI 2022. We have had 4 research abstracts accepted for presentation, and our CSO Asger Bihlet will be presenting at the OARSI Clinical Trial Symposium on the topic: “The Pain of OA – Deconstruction of Pain and Patient Reported Outcomes (PROs) for the Benefit of Patients and Clinical Trial Design”
We are proud to contribute to this year’s Osteoarthritis Research Society International (OARSI) conference, which will be held 7th-10th April in Berlin. The conference will be a hybrid between physical- and online presence.
The aim of the OARSI conference is for scientists and healthcare professionals focused on research to develop better prevention and treatment of osteoarthritis (OA). It promotes and encourages research in OA and disseminates the results to provide a better knowledge of OA and the possible treatments.
Delegates from NBCD management and the science-team will be present at the conference, where they will be presenting 4 research abstracts:
- Abstract: “Correlations between biochemical markers of cartilage turnover, pain categories, and baseline characteristics in a clinical osteoarthritis study, EFEX-OA-02”
- Abstract: “Changes in plasma volume when measuring biochemical markers in relation to acute physical activity in osteoarthritis”
- Abstract: “A randomized, cross-over study to investigate the effect of weight-bearing vs non-weight-bearing exercise and cardiovascular stress on type II collagen turnover in patients with knee osteoarthritis – Serum biomarker data from the EFEX-OA-02 study”
- Abstract: "The efficacy and safety of a fixed-dosed combination of Apocynin and Paeonol in symptomatic knee OA: A double-blind, randomized, placebo-controlled clinical trial"
Furthermore, NBCD will be present at the Clinical Trials Symposium on 6th April, where CSO Asger R. Bihlet will be giving a talk:
- “The Pain of OA – Deconstruction of Pain and Patient Reported Outcomes (PROs) for the Benefit of Patients and Clinical Trial Design”